top of page
Key considerations and best practices for viral vaccine process development, scale-up and implementation at manufacturing scale including single use technologies
M9
Course Goals
Process development and scale-up of viral vaccines.
Timeline
Application Deadline:
1 June 2021
Course Dates:
September 21st (PM), 22nd (Full day) and 23rd (AM)
Organiser
Vaccine Formulation Insitute (VFI) in collaboration with Merck/M Lab, Molsheim, France
Participant Nr.: 10
Contact
Jerôme Dalin
jerome.dalin@merckgroup.com
Maria Lawrenz maria.lawrenz@vformulation.org
Course content
Review of the different vaccines modalities (Core and New)
Using a combination of theory and hands-on instruction, participants will learn the following:
Key best practices and methods for vaccine process development from upstream to downstream focusing on a viral vaccine platform.
Best practices of cell culturing in single use bioreactors for both adherent and suspension cells;
Optimization of filtration and purification technologies;
Adjuvant filtration;
How to integrate vaccine processes in a single use environment;
Learning Outcomes
Understand challenges and integrate key considerations for optimal viral vaccine process development and transition to manufacturing Learn how to implement a single use technology based process for viral vaccines.
Who should apply
This course is designed for R&D scientists and engineers who are or will be responsible for developing and implementing production scale viral vaccine processes.
Minimal requirements
Prior experience with laboratory scale vaccine and/or biologics process development.
Accommodation
Due to COVID19 this course will be held virtually.
Comments
* Due to COVID19 related delays call and training modules' schedule may be subject to change.
Weblink
NA
How to apply>>
Kindly note that not all courses are open for application submission, check open calls to know which for which courses you can apply for at the moment.
Be the first to know about the upcoming application calls, follow European Vaccine Initiative on Twitter and LinkedIn or subscribe to TRANSVAC Newsletter
bottom of page